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diagnosis at inclusion, along with the ICIQ-UI SF score. After
six months, the treatment outcome was clinically evaluated and
the ICIQ-UI SF was newly applied. Mean pre and post-treatment
ICIQ-UI SF scores were compared for the whole sample and for
the two treatment groups. Mean scores were also compared
between “cured” patients and the rest (“improved” or “no
change”). Reliability was assessed with the Cronbachxs alpha
before and after treatment. Percentage of agreement and
Cohenxs Kappa were calculated for the ICIQ-UI SF with respect
to clinical outcomes. RESULTS: From all the patients treated
with PFT (N = 53), 26 (54.2%) were cured. From all the patients
treated with surgery (N = 62), 35 (62.5%) were cured. Post-treat-
ment scores were lower than pre-treatment scores: 4.1 (3.6) vs.
12.3 (4.3) for PFT (p = 0.000); and 2.1 (4) vs. 11.1 (6.3) for
surgery (p = 0.000). Post-treatment scores for cured patients
were lower than that of not cured 2.4 (3) vs. 5.2 (3.3) for PFT
(p = 0.03); and 0.7 (1.3) vs. 4.5 (5.8) for surgery (p = 0.008).
Pre- and post-treatment Cronbachxs alpha were 0.91 and 0.94.
The agreement for the ICIQ-UI SF was moderate. CONCLU-
SIONS: The Spanish version of the ICIQ-SF questionnaire can
adequately evaluate the change after treatment in groups of
patients with SUI.
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OBJECTIVES: To validate a questionnaire assessing the activity
impairment associated with uncomplicated urinary tract infec-
tion (uUTI). METHODS: The Activity Impairment Assessment
(AIA) is a self-administered, ﬁve-item questionnaire assessing the
amount of time an individuals work or regular activities have
been impaired as a result of their UTI. The measure was com-
pleted by 276 women with uUTI who had participated in a
prospective, open-label, non-comparative multi-centre clinical
trial of CIPRO® XR (ciproﬂoxacin extended-release tablets).
Subjects completed the AIA in electronic format at visit one
(prior to ﬁrst dose), then every 24 hours until their regular daily
activities had been unimpaired by their UTI for 24 hours. The
measure was completed at Test of Cure (TOC) visit if the UTI
symptoms had persisted or if regular daily activities were
impaired. Baseline scores on the King’s Health Questionnaire
(KHQ) were collected for validation purposes. A clinical evalu-
ation of UTI symptoms at baseline and TOC visit was per-
formed. RESULTS: Principal component analysis of the AIA
revealed one component with an eigenvalue > 1, explaining
78.6% of the variance. All items loaded >0.84 on this single com-
ponent. Rasch analysis showed that the AIA displayed an excel-
lent ﬁt to the Rasch model, supporting the factor structure. The
AIA was found to have internal consistency (0.93). It shared sig-
niﬁcant relationships with relevant KHQ domains (all rs > 0.70)
supporting its convergent validity, divergent validity was sup-
ported by a lack of relationship between the total score and a
unrelated KHQ domain (r = 0.078). The AIA displayed excellent
discriminant validity for clinical evaluations of dysuria, fre-
quency, urgency, and suprapubic pain. It was also found to be
responsive to change across all clinical evaluations. CONCLU-
SIONS: The uni-dimensional AIA shows high levels of internal
reliability, convergent and divergent validity, discriminant valid-
ity and responsiveness. It is an excellent tool for activity impair-
ment in UTI.
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OBJECTIVES: Dialysis patients have a chronic disease. For these
patients, process characteristics of their treatment are important.
Therefore this study aimed at the development and testing of a
questionnaire to assess the quality of care in Dutch dialysis
centres from the patient’s perspective: the Quality of Care in
Dialysis centres Questionnaire (QCDQ). METHODS: In a liter-
ature study, possible sets of dimensions were identiﬁed. Four
focus group sessions were organized, with 27 patients in total.
The results from the focus groups were transformed into a 68-
item test version of the QCDQ. This test version was discussed
with four nephrologists and seven patients. A visual analogue
scale (VAS) was added to determine overall satisfaction. The test
version was sent to 300 patients in a postal setting. Factor analy-
sis was applied and item reductions were conducted. The result-
ing QCDQ was subsequently distributed in ten dialysis centres
in order to test its performance. RESULTS: Statistical analyses
of the test version were based on 140 out of 162 returned ques-
tionnaires. The results from the factor analysis conﬁrmed the use
of the set of dimensions with the dimensions: doctors, nurses,
other staff members, and facilities. After item reduction 36 items
and the VAS remained. Each dimension consists of eight speciﬁc
items and one item about the overall satisfaction with that
dimension. Statistical analyses of this 36-item questionnaire were
based on 331 out 511 returned questionnaires. The QCDQ is an
instrument that is content valid, construct valid and reliable (a
= 0.91). CONCLUSIONS: The QCDQ can be used in Dutch
dialysis centres. Further research will be conducted to establish
preference weights per dimension on the basis of the VAS scores.
These preference weights can be applied in benchmark proce-
dures to assess the quality of care in a dialysis centre.
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OBJECTIVES: 1) To estimate the prevalence of stress urinary
incontinence (SUI) in French women; 2) to measure the impact
of SUI severity on quality of life; and 3) to identify sociodemo-
graphic factors associated with the severity of SUI. METHODS:
In a cross-sectional study 5160 randomly selected women (age
18 to 70 years) were interviewed by phone in 2002. The SUI was
deﬁned as “having had at least one episode of urine leakage
during the past 30 days at time of effort”. Pregnant women or
women with less than three months since last delivery were
excluded. Women suffering from SUI were classiﬁed into two
groups according to the frequency of urine losses: 1)ﬁrst group:
> two urine losses per day; and 2)second group: < two urine
losses per day. The effects of the symptoms on the quality of life
were evaluated using the validated French version of the Contil-
ife© scale. This scale includes a global index of quality of life
and six sub-domains. Furthermore, additional data were col-
lected on the demographic proﬁle of these women (age, number
of children, education level). Relationships between level of
urinary symptoms and patient characteristics were measured
using analysis of variance and chi-square tests where appropri-
ate. RESULTS: The actual prevalence of female SUI was 19.4%
(CI95%: 18.3, 20.5). Among the women suffering from SUI,
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9.1% had at least 14 urine losses per week. Level of symptoms
was closely related quality of life. Comparing the two groups,
we observed some relationships between level of symptoms and
socio-demographics. CONCLUSIONS: Prevalence of SUI in
French women was high. Women with SUI had a marked
decrease in their quality of life. There was an inverse relation
between level of urinary symptoms and quality of life: as the
intensity of symptoms increased, the quality of life decreased.
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OBJECTIVES: In October 2000, the ICD-9 diagnosis code
596.51 “Hypertonicity of Bladder” was updated to include
“Overactive Bladder” (OAB). Previously, no speciﬁc code iden-
tiﬁed OAB. To determine implications for outcomes estimates,
this study examined correspondence between suggested ICD-9
coding for OAB before the update and use of codes in claims
data. METHODS: Data were drawn from medical claims of
enrollees aged ≥18 years of a large US health plan. Fifteen ICD-
9 diagnosis codes that might indicate OAB were identiﬁed
through literature review and clinical consultation, and exam-
ined for agreement between sources. Possible OAB patients were
identiﬁed if an OAB ICD-9 code appeared in claims from August
31, 1999–March 1, 2000. RESULTS: Sources agreed completely
on ﬁve of 15 suggested ICD-9 codes. Of 33,290 patients with
suggested codes, 86% had 1 of the 5 codes, and only 1% had
596.51 “Hypertonicity of Bladder” before the added OAB
description. Most commonly used were “Urinary Frequency”
(788.41; 48% of possible patients), “Unspeciﬁed Urinary Incon-
tinence” (788.30; 19%), “Nocturia” (788.43; 15%), “Urge
Incontinence” (788.31; 8%), and “Mixed Incontinence, Urge
and Stress” (788.33; 5%). Proportion of subjects with the 5
codes differed by geographic region (p < 0.0001), but not by
gender (c2 = 3.30, p = 0.07). Of 15 codes, “Nocturia” (788.43)
was the only code with a greater proportion (74%) of men. Use
of the ﬁve primary codes showed a linear trend (p < 0.0001)
increasing from 81% in ages 18–35 to 91% in ages ≥75. CON-
CLUSIONS: Before the ICD-9 code update, ﬁve codes accounted
for most possible OAB patients and few were coded with 596.51.
We expect claims data following the October 2000 implementa-
tion will gradually shift to the updated OAB code. Research
should include 596.51 and the other ﬁve codes because coding
practices may change and demographic coding differences could
have an impact on outcomes estimates.
PUK21
AN ANALYSIS OF PATIENTS ON WAITING LISTS TO RECEIVE
SURGERY FOR STRESS URINARY INCONTINENCE (SUI) IN
ENGLAND AND SCOTLAND
McAllister R1, Das Gupta R2, Piercy J3, Ryan J1
1Mapi Values Ltd, Macclesﬁeld, Cheshire, UK; 2Boehringer-Ingelheim,
Bracknell, UK; 3Adelphi Group, UK
OBJECTIVES: To analyse waiting lists and waiting times for
female patients with SUI in order to determine their burden on
Gynaecology and Urology National Health Service (NHS)
waiting lists waiting for SUI procedures. METHODS: The CHKS
hospital database in the UK was analysed over a two year period
for patients admitted for surgery between April, 2001 and
March, 2003. Speciﬁc SUI procedures were identiﬁed within
Gynaecology and Urology specialties and the number of cases
waiting for these procedures at speciﬁc time points was derived.
Results are presented as an average across the ﬁnancial year
2001–2002 as this data was considered most complete. Results
were stratiﬁed by England, Scotland and specialty. RESULTS:
England: 3.38% of patients on the Gynaecology waiting list and
2.90% of patients on the Urology waiting list are waiting for SUI
procedures. The mean and median wait times for Gynaecology
were 313 and 309 days respectively and for Urology 343 and
350 days respectively. The mean age of patients admitted to
Gynaecology was 54.76 and Urology was 56.98. Scotland:
4.25% of patients on the Gynaecology waiting list and 3.30%
of patients on the Urology waiting list are waiting for an SUI
procedure. The mean and median wait times for Gynaecology
were 175 and 142 days respectively and for Urology 268 and
275 days respectively. The mean age of patients admitted to
Gynaecology was 51.64 and Urology was 54. CONCLUSIONS:
The percentage of patients waiting for an SUI procedure repre-
sents a signiﬁcant burden on the NHS where, in England, there
is an average of 2866 patients on the gynaecology waiting list
and 2080 on the Urology waiting list in any one quarter between
2001–2002 waiting for SUI procedures. Any new treatment
reducing the need for SUI procedures could potentially have a
noticeable impact on waiting lists in the NHS.
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OBJECTIVES: To collect and compare unit costs for resource
use data in PURE, an observational study with the primary
objective to determine the direct cost of urinary incontinence (UI)
treatment in Europe. METHODS: Resource use data include
medication, conservative treatment, diagnostic and surgical pro-
cedures, incontinence products and visits to health care
providers. Unit costs by country and type were collected using a
standardized data collection form. OECD consumer price indices
and purchasing power parity ﬁgures were used to convert prices
into 2003/2004 values and US dollars respectively. Prices were
then converted into Euros using an exchange rate of 1$ = 0.84€
(June 2004). RESULTS: Unit costs were derived from standard
national pricelists for medications, retail prices for incontinence
products, DRG (Diagnosis-related Groups) data for surgical
interventions where applicable, or costs of procedures and
overnight stays derived from hospitals in the remaining coun-
tries. The costs of conservative therapy, incontinence products
and health care visits varied between countries within reasonable
